This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

8 Stocks Ripping Higher on Big Volume

Theravance

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Theravance (THRX - Get Report) is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. This stock is trading up 7.5% at $23.90 in recent trading.

Today's Volume: 552,000

Average Volume: 499,830

Volume % Change: 107%

Shares of BMRN are soaring higher today after Piper Jaffray highlighted the stock has a potential takeover target in the biotech space following Bristol-Myers' (BMY) acquisition of Amylin (AMLN). Piper believes an acquisition of BioMarin could be valued at $79 per share.

>>22 Biopharma Stocks With Breakout Potential in 2012

From a technical perspective, THRX is gapping up sharply here with above average volume. This move has pushed THRX into breakout territory, since shares have taken out some near-term overhead resistance at $22.93. Traders should now watch for the next major breakout trade to trigger for THRX. That trade will hit once THRX takes out its April high of $24.29 with high-volume.

Traders should look for long-biased trades once THRX sustains a move or close above $24.29 with volume that's near or above 499,830 shares. If we get that action soon, then THRT has a great chance of re-testing and possibly taking out its 52-week high of $25.40 in the near future.

As of the most recently reported period, Theravance was one of Seth Klarman's Baupost Group holdings.
3 of 9

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
ALGN $62.50 0.00%
AMRN $2.50 0.00%
BMRN $140.10 0.00%
THRX $16.01 0.00%
AAPL $126.00 0.00%

Markets

DOW 17,683.58 -46.53 -0.26%
S&P 500 2,068.76 -8.02 -0.39%
NASDAQ 4,991.94 -17.2740 -0.34%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs